Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:34:21 29/06/2024 am IST			5-day change	1st Jan Change
123.8 ^USD	-4.64%		-5.29%	+13.56%

28/06	Merck: positive opinion for Winrevair in Europe	CF
28/06	Merck Gets CHMP Backing of Winrevair in Pulmonary Arterial Hypertension	DJ

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

January 24, 2024 at 01:14 am IST

Merck announced that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company?s common stock for the second quarter of 2024. Payment will be made on April 5, 2024, to shareholders of record at the close of business on March 15, 2024.

Latest news about Merck & Co., Inc.

Merck: positive opinion for Winrevair in Europe	28/06	CF
Merck Gets CHMP Backing of Winrevair in Pulmonary Arterial Hypertension	28/06	DJ
Merck Says European Medicines Agency's Committee Recommends Approval of Heart Disease Drug Winrevair	28/06	MT
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older	28/06	RE
Merck: ACIP recommends Capvaxive for people over 65	28/06	CF
Merck Says CDC's Advisory Committee Unanimously Recommends Pneumococcal Vaccine for Some Adults	28/06	MT
CDC?S ACIP Unanimously Recommends Merck?s CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults	28/06	CI
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	27/06	DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
Merck: FDA response on patritumab deruxtecan	27/06	CF
Aqilion Announces the Termination of the Licensing and Collaboration Agreement with Merck for the Joint Development of the TAK1 Programme Taking Aim at Chronic Inflammation	27/06	CI
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	CI
Merck: US approval for canine flu vaccine	26/06	CF
Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine	26/06	MT
Merck Animal Division's Dog Flu Treatment Gets Agriculture Department Approval	26/06	DJ
China grants license to Merck's KEYTRUDA for stomach cancer treatment	25/06	RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...	18/06
Merck: FDA approves Capvaxive pneumococcal vaccine	18/06	CF
Merck: new FDA approval for Keytruda	18/06	CF
Big tech still runs the show	18/06
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	18/06	MT
Wall Street set for flat open after soft retail sales data	18/06	RE
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	18/06	MT
Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment	18/06	MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer	18/06	DJ

Chart Merck & Co., Inc.

Duration

Period

More charts

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

123.8 USD

Average target price

142.7 USD

Spread / Average Target

+15.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+13.56%	31TCr
ELI LILLY AND COMPANY	+55.32%	82TCr
JOHNSON & JOHNSON	-6.75%	35TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	22TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr
SANOFI	+0.20%	12TCr

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

EPS Revisions